Age, Biography and Wiki

Howard E. Gendelman was born on 18 March, 1954 in Philadelphia, Pennsylvania, USA. Discover Howard E. Gendelman's Biography, Age, Height, Physical Stats, Dating/Affairs, Family and career updates. Learn How rich is He in this year and how He spends money? Also learn how He earned most of networth at the age of 69 years old?

Popular As N/A
Occupation N/A
Age 70 years old
Zodiac Sign Pisces
Born 18 March, 1954
Birthday 18 March
Birthplace Philadelphia, Pennsylvania, USA
Nationality United States

We recommend you to check the complete list of Famous People born on 18 March. He is a member of famous with the age 70 years old group.

Howard E. Gendelman Height, Weight & Measurements

At 70 years old, Howard E. Gendelman height not available right now. We will update Howard E. Gendelman's Height, weight, Body Measurements, Eye Color, Hair Color, Shoe & Dress size soon as possible.

Physical Status
Height Not Available
Weight Not Available
Body Measurements Not Available
Eye Color Not Available
Hair Color Not Available

Dating & Relationship status

He is currently single. He is not dating anyone. We don't have much information about He's past relationship and any previous engaged. According to our Database, He has no children.

Parents Not Available
Wife Not Available
Sibling Not Available
Children Not Available

Howard E. Gendelman Net Worth

His net worth has been growing significantly in 2022-2023. So, how much is Howard E. Gendelman worth at the age of 70 years old? Howard E. Gendelman’s income source is mostly from being a successful . He is from United States. We have estimated Howard E. Gendelman's net worth , money, salary, income, and assets.

Net Worth in 2023 $1 Million - $5 Million
Salary in 2023 Under Review
Net Worth in 2022 Pending
Salary in 2022 Under Review
House Not Available
Cars Not Available
Source of Income

Howard E. Gendelman Social Network




Gendelman was the first to pharmacologically transform effector into regulatory T cells to halt the progression of Parkinson's disease. Phase II investigation began in early 2021 after successful phase I investigations


Gendelman's group was among the first to reverse HIV-dementia in an infected person using combination antiretroviral therapy (cART), and they developed scores of rodent models to mimic HIV/AIDS end-organ disease. He coined the term long-acting slow effective release ART (LASER ART). These works led to polymer discovery, targeted drug delivery to viral reservoirs, and reduction of residual virus in lymphoid organs. His Nebraska-based research group, along with a team at Temple University, was also the first to combine HIV reservoir-targeted LASER ART and CRISPR-Cas9 to eliminate chronic viral infection from infected animals. This curative approach (published in Nature Communications, 2019) received considerable attention in establishing a novel translational pathway for HIV eradication. This work followed the first ultra-long acting nanocrystal prodrug and the world's first HIV vaccine mimetic (in Nature Materials, 2020). His work with cell-based drug delivery born out of nanoparticle-mononuclear phagocyte interactions has inspired broad pharmaceutical interest; in turn, Gendelman led the establishment of the Nebraska Nanomedicine Production Plant, a biotechnology good manufacturing practices (cGMP) initiative, to position research for clinical translation in the development of long acting nanoformulated ART at UNMC. He also co-founded Exavir Therapeutics, Inc., a biotechnology company developing therapies towards and cure for HIV/AIDS.


Gendelman worked at the National Institute of Allergy and Infectious Diseases during the height of the HIV/AIDS Pandemic. Gendelman also occupied senior faculty and research positions at the Johns Hopkins Medical Institutions, the Uniformed Services University of the Health Sciences Center, the Walter Reed Army Institute of Research, and the Henry M. Jackson Foundation for the Advancement in Military Medicine before joining the faculty of UNMC in March 1993. He retired from the US Army with the rank of Lieutenant Colonel. He established the Center for Neurovirology and Neurodegenerative Disorders at UNMC in 1997, which evolved into UNMC's current Department of Pharmacology and Experimental Neuroscience in 2004. In 2000, he was awarded a Fulbright to do research at the Weizmann Institute of Science in Rehovot, Israel


Gendelman graduated with a bachelor's degree in Natural Sciences and Russian Studies from Muhlenberg College (1971-1975).


Howard E. Gendelman (born March 18, 1954) is an American physician-scientist whose research intersects the disciplines of neuroimmunology, pharmacology, and infectious diseases. Gendelman was born in Philadelphia, Pennsylvania. His research is focused on harnessing immune responses for therapeutic gain in HIV/AIDS and Neurodegenerative disease. He is the Margaret R. Larson Professor of infectious diseases and internal medicine at the University of Nebraska Medical Center (UNMC) in Omaha.